3.29
price up icon0.30%   0.01
after-market アフターアワーズ: 3.30 0.010 +0.30%
loading
前日終値:
$3.28
開ける:
$3.3
24時間の取引高:
3.19M
Relative Volume:
0.81
時価総額:
$716.89M
収益:
$35.54M
当期純損益:
$-59.14M
株価収益率:
-9.0459
EPS:
-0.3637
ネットキャッシュフロー:
$-80.19M
1週間 パフォーマンス:
-4.64%
1か月 パフォーマンス:
+1.54%
6か月 パフォーマンス:
-39.52%
1年 パフォーマンス:
+55.19%
1日の値動き範囲:
Value
$3.175
$3.38
1週間の範囲:
Value
$3.175
$3.60
52週間の値動き範囲:
Value
$1.90
$8.21

Cytomx Therapeutics Inc Stock (CTMX) Company Profile

Name
名前
Cytomx Therapeutics Inc
Name
セクター
Healthcare (1033)
Name
電話
650.515.3185
Name
住所
151 OYSTER POINT BLVD., SOUTH SAN FRANCISCO, CA
Name
職員
69
Name
Twitter
@cytomxinc
Name
次回の収益日
2026-08-06
Name
最新のSEC提出書
Name
CTMX's Discussions on Twitter

Compare CTMX vs VRTX, REGN, ARGX, MRNA, RVMD

株式 価格 時価総額 収益 当期純利益 現金流量 EPS
CTMX icon
CTMX
Cytomx Therapeutics Inc
3.29 716.89M 35.54M -59.14M -80.19M -0.3637
VRTX icon
VRTX
Vertex Pharmaceuticals Inc
547.59 136.93B 12.34B 4.34B 3.71B 16.87
REGN icon
REGN
Regeneron Pharmaceuticals Inc
828.50 85.11B 14.92B 4.42B 3.79B 41.04
ARGX icon
ARGX
Argen X Se Adr
1,011.11 64.95B 4.16B 1.29B 734.26M 19.58
MRNA icon
MRNA
Moderna Inc
138.89 53.23B 2.23B -3.19B -1.60B -8.1462
RVMD icon
RVMD
Revolution Medicines Inc
211.58 45.38B 742.00K -1.37B -1.07B -7.0731

Cytomx Therapeutics Inc Stock (CTMX) Upgrades & Downgrades

日付 アクション アナリスト 評価の変更
2026-03-16 アップグレード JP Morgan Neutral → Overweight
2026-01-20 開始されました Guggenheim Buy
2025-09-22 開始されました Cantor Fitzgerald Overweight
2025-09-17 再開されました Barclays Overweight
2025-07-31 開始されました Oppenheimer Outperform
2025-05-15 アップグレード H.C. Wainwright Neutral → Buy
2025-04-14 再開されました Piper Sandler Overweight
2024-05-28 アップグレード Piper Sandler Neutral → Overweight
2024-05-09 アップグレード Wedbush Neutral → Outperform
2024-05-06 アップグレード Jefferies Hold → Buy
2024-04-22 アップグレード JP Morgan Underweight → Neutral
2022-11-14 ダウングレード BMO Capital Markets Outperform → Market Perform
2022-07-07 ダウングレード Jefferies Buy → Hold
2022-07-07 ダウングレード Mizuho Buy → Neutral
2022-07-07 ダウングレード Piper Sandler Overweight → Neutral
2022-07-07 ダウングレード Wedbush Outperform → Neutral
2022-06-24 開始されました BMO Capital Markets Outperform
2022-01-18 アップグレード Barclays Underweight → Overweight
2021-11-15 開始されました BTIG Research Buy
2021-05-28 ダウングレード Barclays Equal Weight → Underweight
2021-03-29 開始されました JP Morgan Overweight
2021-03-23 アップグレード Jefferies Hold → Buy
2020-09-22 ダウングレード Guggenheim Buy → Neutral
2020-06-01 ダウングレード Jefferies Buy → Hold
2020-05-14 繰り返されました H.C. Wainwright Buy
2020-03-24 アップグレード Wedbush Neutral → Outperform
2020-03-04 開始されました Barclays Equal Weight
2019-11-20 開始されました Guggenheim Buy
2019-11-11 ダウングレード Wedbush Outperform → Neutral
2019-06-13 開始されました Mizuho Buy
2019-05-14 開始されました Cantor Fitzgerald Overweight
2019-03-11 開始されました Barclays Overweight
2018-11-26 開始されました Piper Jaffray Overweight
2018-10-15 開始されました Goldman Neutral
2018-09-13 開始されました H.C. Wainwright Buy
2018-06-01 開始されました SunTrust Buy
2018-01-05 開始されました Citigroup Buy
2017-09-08 開始されました Wedbush Outperform
2017-03-27 開始されました H.C. Wainwright Buy
2017-03-02 開始されました Instinet Buy
2017-01-03 ダウングレード Oppenheimer Outperform → Perform
2015-11-02 開始されました Oppenheimer Outperform
すべてを表示

Cytomx Therapeutics Inc (CTMX) 最新ニュース

pulisher
Aug 21, 2026

CytomX Therapeutics (NASDAQ:CTMX) Downgraded to "Hold" Rating by Zacks Research - MarketBeat

Aug 21, 2026
pulisher
Aug 15, 2026

CytomX Therapeutics (NASDAQ:CTMX) Stock Rating Upgraded by Wall Street Zen - MarketBeat

Aug 15, 2026
pulisher
Aug 14, 2026

Point72’s 3.6% CytomX Therapeutics (CTMX) stake detailed in amended filing - Stock Titan

Aug 14, 2026
pulisher
Aug 14, 2026

Kynam Capital reports 9.96% CytomX Therapeutics (CTMX) ownership in Schedule 13G/A - Stock Titan

Aug 14, 2026
pulisher
Aug 14, 2026

CytomX Therapeutics, Inc.: Target Price Consensus and Analysts Recommendations | CTMX | US23284F1057 - marketscreener.com

Aug 14, 2026
pulisher
Aug 13, 2026

CTMX Maintained by JP Morgan -- Price Target Lowered to $11.00 - GuruFocus

Aug 13, 2026
pulisher
Aug 13, 2026

CytomX Therapeutics (NASDAQ:CTMX) Given New $11.00 Price Target at JPMorgan Chase & Co. - MarketBeat

Aug 13, 2026
pulisher
Aug 13, 2026

CytomX Therapeutics Is Maintained at Overweight by JP Morgan - Moomoo

Aug 13, 2026
pulisher
Aug 13, 2026

Bank of America Corp DE Has $47.95 Million Position in CytomX Therapeutics, Inc. $CTMX - MarketBeat

Aug 13, 2026
pulisher
Aug 13, 2026

MSN Money - MSN

Aug 13, 2026
pulisher
Aug 12, 2026

CytomX Therapeutics: Promising Varseta-M With Comfortable Runway (NASDAQ:CTMX) - Seeking Alpha

Aug 12, 2026
pulisher
Aug 10, 2026

CTMX Maintained by Guggenheim -- Price Target Lowered to $14.00 - GuruFocus

Aug 10, 2026
pulisher
Aug 10, 2026

Guggenheim cuts CytomX stock price target to $14 on model update - Investing.com South Africa

Aug 10, 2026
pulisher
Aug 10, 2026

CytomX Therapeutics, Inc. $CTMX Shares Purchased by Dimensional Fund Advisors LP - MarketBeat

Aug 10, 2026
pulisher
Aug 09, 2026

Q2 2026 CytomX Therapeutics Inc Earnings Call Transcript - GuruFocus

Aug 09, 2026
pulisher
Aug 09, 2026

Q4 2025 CytomX Therapeutics Inc Earnings Call Transcript - GuruFocus

Aug 09, 2026
pulisher
Aug 08, 2026

CytomX Therapeutics (CTMX) Stock Faces Revenue Collapse As Pipeline Hopes Carry The Story - Sahm

Aug 08, 2026
pulisher
Aug 08, 2026

CytomX Therapeutics, Inc. (NASDAQ:CTMX) Given Average Rating of "Buy" by Brokerages - MarketBeat

Aug 08, 2026
pulisher
Aug 08, 2026

CytomX Therapeutics (NASDAQ:CTMX) Announces Earnings Results - MarketBeat

Aug 08, 2026
pulisher
Aug 07, 2026

CytomX Therapeutics, Inc. Stock 12‑Month Price Target Cut to $12.38, Implies 267% Upside - TradingView

Aug 07, 2026
pulisher
Aug 07, 2026

State Street Corporation (CTMX) reports 5.4% beneficial stake in CytomX Therapeutics - Stock Titan

Aug 07, 2026
pulisher
Aug 07, 2026

CytomX Therapeutics Inc (CTMX) (Q2 2026) Earnings Call Highlight - GuruFocus

Aug 07, 2026
pulisher
Aug 07, 2026

CytomX Therapeutics Inc (CTMX) (Q2 2026) Earnings Call Highlights: Varetta M Advances Toward ... - Yahoo Finance

Aug 07, 2026
pulisher
Aug 06, 2026

CytomX Therapeutics secures $37M from Regeneron amid Q2 revenue miss - scanx.trade

Aug 06, 2026
pulisher
Aug 06, 2026

CytomX Q2 2026 Earnings: Revenue Falls as R&D Spending Rises - TradingKey

Aug 06, 2026
pulisher
Aug 06, 2026

CytomX Therapeutics Q2 Earnings Call Highlights - marketbeat.com

Aug 06, 2026
pulisher
Aug 06, 2026

CTMX Looks 1148.1% Overvalued on GF Value™ - GuruFocus

Aug 06, 2026
pulisher
Aug 06, 2026

Earnings call transcript: CytomX misses Q2 2026 estimates as cash runway extends - Investing.com

Aug 06, 2026
pulisher
Aug 06, 2026

CytomX Therapeutics (CTMX) Reports Q2 Loss, Lags Revenue Estimates - Yahoo Finance

Aug 06, 2026
pulisher
Aug 06, 2026

Is CytomX Therapeutics Inc (CTMX) Facing Financial Headwinds Aft - GuruFocus

Aug 06, 2026
pulisher
Aug 06, 2026

CytomX Therapeutics, Inc. reports results for the quarter ended June 30Earnings Summary - TradingView

Aug 06, 2026
pulisher
Aug 06, 2026

CytomX Therapeutics Announces Q2 2026 Financial Results and Provides Business Update - The Manila Times

Aug 06, 2026
pulisher
Aug 06, 2026

CytomX enrolls 113 patients; next colorectal cancer trial planned - Stock Titan

Aug 06, 2026
pulisher
Aug 06, 2026

CytomX Therapeutics posts Q2 2026 results — $1.4M revenue, $25.2M operating expense, $330.3M cash - TradingView

Aug 06, 2026
pulisher
Aug 06, 2026

CytomX Therapeutics 2Q 2026: Revenue $1.42M, EPS $(0.09) — 10-Q Summary - TradingView

Aug 06, 2026
pulisher
Aug 05, 2026

CytomX Therapeutics, Inc. (CTMX) awards 450,000 options and 100,000 RSUs to CLO - Stock Titan

Aug 05, 2026
pulisher
Aug 05, 2026

CytomX Therapeutics, Inc. (CTMX) Chief Legal Officer files Form 3 insider report - Stock Titan

Aug 05, 2026
pulisher
Aug 03, 2026

Bank of America (NYSE: BAC) discloses 7.0% ownership stake in CytomX (CTMX) - Stock Titan

Aug 03, 2026
pulisher
Aug 03, 2026

CytomX Therapeutics Appoints Alejandra Carvajal as Chief Legal Officer - The Manila Times

Aug 03, 2026
pulisher
Aug 03, 2026

Press Release: CytomX Therapeutics Appoints Alejandra Carvajal as Chief Legal Officer - Moomoo

Aug 03, 2026
pulisher
Aug 02, 2026

DV Trading LLC Makes New $3.36 Million Investment in CytomX Therapeutics, Inc. $CTMX - MarketBeat

Aug 02, 2026
pulisher
Jul 31, 2026

BlackRock, Inc. Adds to CytomX Therapeutics Inc (CTMX) Stake -- Shares Look 1007% Overvalued on GF Value - GuruFocus

Jul 31, 2026
pulisher
Jul 31, 2026

Form 4 CytomX Therapeutics Inc For: 31 July By Investing.com - Investing.com Nigeria

Jul 31, 2026
pulisher
Jul 30, 2026

CytomX Therapeutics to Report Second Quarter 2026 Financial Results on August 6, 2026 - The Manila Times

Jul 30, 2026
pulisher
Jul 30, 2026

CytomX Therapeutics Announces Date for Second Quarter 2026 Financial Results Conference Call - Quiver Quantitative

Jul 30, 2026
pulisher
Jul 29, 2026

Ally Bridge Group NY LLC Makes New $4.23 Million Investment in CytomX Therapeutics, Inc. $CTMX - MarketBeat

Jul 29, 2026
pulisher
Jul 28, 2026

CytomX Therapeutics, Inc. $CTMX Stake Lifted by Elmind Capital LP - MarketBeat

Jul 28, 2026
pulisher
Jul 27, 2026

BlackRock (CTMX holder) discloses 7.6% beneficial stake in CytomX Therapeutics - Stock Titan

Jul 27, 2026
pulisher
Jul 27, 2026

CytomX appoints Charles Fuchs to board of directors By Investing.com - Investing.com South Africa

Jul 27, 2026
pulisher
Jul 27, 2026

CytomX Therapeutics Inc (CTMX) Shareholder Structure: Major Shareholders & Institutional Holdings - TradingKey

Jul 27, 2026
pulisher
Jul 27, 2026

CytomX Therapeutics Announces Appointment of Charles Fuchs, M.D., M.P.H., to the Board of Directors - The Manila Times

Jul 27, 2026

Cytomx Therapeutics Inc (CTMX) 財務データ

収益

loading

当期純利益

loading

現金流量

loading

EPS

loading

Cytomx Therapeutics Inc (CTMX) インサイダートレーディング

インサイダートレーディング 関係 日付 取引 コスト #株式 値 ($) #株式総数
Chu Yu-Waye
Chief Medical Officer
Mar 17 '26
Sale
6.42
21,279
136,675
189,446
McCarthy Sean A.
CEO
Mar 17 '26
Sale
6.42
118,969
764,138
1,078,922
BELVIN MARCIA
SVP, Chief Scientific Officer
Mar 17 '26
Sale
6.42
31,492
202,273
300,760
Ogden Christopher
Chief Financial Officer
Mar 17 '26
Sale
6.42
19,323
124,112
296,948
McCarthy Sean A.
CEO
Nov 06 '25
Sale
4.54
101,793
461,906
987,891
$123.98
price up icon 0.00%
$61.33
price up icon 0.03%
$112.82
price down icon 3.22%
$236.01
price down icon 0.09%
ONC ONC
$371.98
price down icon 0.66%
$211.58
price up icon 1.01%
大文字化:     |  ボリューム (24 時間):